Ms. Pigg is a forward thinking health care executive who has diverse experience with a broad array of health care organizations and products including commercial, Medicare and Medicaid lines of business. In her role as SVP/Chief Pharmacy Officer for Gateway, Cynthia combines her expertise in strategic planning with tactical practices to manage the pharmacy department’s financial performance, cost management and containment, policies and quality improvement, while maintaining high levels of member satisfaction. As the senior leader in Pharmacy, she collaborates with medical management teams to develop programs that engage members and enhance “best-in-class” care management, while managing and improving Gateway’s pharmacy expenses across all business lines.

Previously, Ms. Pigg served as Senior Vice President of Pharmacy for Magellan Health, Inc., where she was responsible for strategic leadership, product innovation, performance improvement, sales and marketing support, customer satisfaction and quality. She has served as CEO of the Foundation for Managed Care Pharmacy and was a Vice President at Cigna Healthcare focusing on Trade Relations, Customer Service and Medical Cost Management.

Ms. Pigg holds an Masters in Health Administration from the Medical College of Virginia/Virginia Commonwealth University and B.S. degrees in Pharmacy and Medical Technology, as well as numerous awards and honors from national and state pharmacy associations. She is also a Fellow of the Academy of Managed Care Pharmacy.

As Chief Medical Officer of BCBSNC, Dr. Caveney leads healthcare program design and strategy, medical management, care management, plan quality initiatives, provider network, and pharmacy for the plan’s 3.9 million members.

Rick Ascroft is responsible for Managed Markets and Government and External Affairs and serves as a member of the Takeda Pharmaceuticals U.S.A, Inc. Executive Team. Mr. Ascroft joined Takeda in November 2015. Mr. Ascroft was also named a board member with the California Life Sciences Association in May 2017.

Prior to joining Takeda, Mr. Ascroft worked for Eli Lilly and Company for twenty-two years in a variety of clinical research, commercial, market access and corporate affairs roles. He has spent well over half of his career working in public affairs and managed markets roles in the US and internationally, spending five years as the Director of Corporate Affairs and Market Access for Emerging Markets and Japan, followed by three years as the Senior Director of Corporate Affairs and Market Access for the UK and Republic of Ireland and most recently four years as the Senior Director of Corporate Affairs, Market Access and Pricing for Europe, Canada and Australia. Prior to these roles, Rick worked in US Federal Public Policy, Clinical Development and Sales.

Mr. Ascroft has a Bachelor of Science degree in pharmacy from Butler University in Indianapolis, Indiana and a law degree from the Indiana University School of Law, graduating summa cum laude.

Dr. Indranil Bagchi is the former Vice President and Head of Payer Insights and Access at Pfizer, where he leads efforts to understand payer perspectives and develop the market access strategy for the entire Pfizer portfolio, including the payer value proposition, pricing strategy and reimbursement support across all disease areas and markets. Indranil has two decades of experience in Pricing & Reimbursement, Health Economics & Outcomes Research, and Market Access across several major companies in the pharmaceutical industry.

Indranil is a frequent speaker and contributor to forums, articles and conferences addressing issues related to access to medicines. In 2014, Indranil received the ‘Outstanding 50 Asian Americans in Business’ award by the Asian American Business Development Center. In 2010, Indranil was recognized in Pharmaceutical Executive magazine’s annual roster of Emerging Leaders, “The New Breed of Leadership.” Due to his efforts in securing and expanding market access for Enbrel, Indranil was awarded the Wyeth President’s Achieving Excellence Award in 2005.

Previously at Pfizer, he was Vice President and Head of Market Access for the Specialty Care Business Unit and prior to that, he was Senior Director/Team Leader in Pfizer’s Global Pricing and Reimbursement Group. Prior to joining Pfizer, Indranil was Senior Director at Wyeth responsible for pricing, reimbursement and market access of products within the Bio-Pharma Business Unit. Before Wyeth, Indranil was first with SmithKline Beecham and subsequently with GlaxoSmithKline with their Health Economics and Outcomes Research departments. Dr. Bagchi has an undergraduate degree in Pharmacy, a master’s degree in Pharmacy and Healthcare Administration and a doctoral degree in Pharmaceutical Socioeconomics.

Joshua Benner, PharmD, ScD, is the President and CEO of RxAnte, a provider of science-based information technology solutions for improving quality and lowering the cost of healthcare. A leading voice on medication adherence, Dr. Benner’s award-winning research and numerous publications have shed new light on the problem of non-adherence and identified promising approaches to improving it. Prior to RxAnte, Dr. Benner was Fellow and Managing Director at the Brookings Institution’s Engelberg Center for Health Care Reform, where he focused on medical technology policy. Prior to Brookings, Dr. Benner was principal at ValueMedics Research, an analytic and consulting services firm. Following the successful sale of ValueMedics to IMS Health in 2007, he served as senior principal in health economics and outcomes research and global lead for medication adherence at IMS. Dr. Benner received his Doctor of Pharmacy degree from Drake University and his Doctor of Science in health policy and management from the Harvard University School of Public Health.

Roman Casciano, MSc, is the General Manager of the Analytica Laser Value + Access teams, and is based in New York City. Roman’s role comprises the coordination and management of the strategic and scientific teams focused on product value demonstration and market access across the company’s 8 offices. Roman continues to actively participate in client engagements as a global market access strategist and tactician, ensuring that our customers can leverage all of the benefits of our multidisciplinary team and integrated offer.

Roman was one of the founding members of the Analytica Group in 1997 and remained with the company for over 14 years, serving in various capacities during his tenure ultimately serving as President from 2008 onwards. Prior to taking on his role as President of Analytica, Roman worked for 2 years in Analytica’s previous parent company, Accentia Biopharmaceuticals as the Sr Vice President and head of the NY-based product development team with full responsibility for the conduct of its two on-going phase III clinical programs.

As an applied health economist and market access strategist, Roman has personally led hundreds of engagements in the international market access and HEOR context related to product value demonstration and has deep experience in the management of multidisciplinary teams of scientific and strategic consultants across continents. Roman’s experience ranges from analytical activities such as economic modelling and database studies, to strategic activities such as developing product pricing and market access plans and communicating evidence internally and externally for our customers. Roman has experience across the product lifecycle, including assessment of early phase assets, licensing due diligence, and go/no-go decision-making support, as well as launch planning and commercialization activities.

Roman received both a Bachelor of Science degree in Mechanical and Aerospace Engineering and a Master of Engineering Degree in Mechanical Engineering and Engineering Decision Making from Cornell University.

Michelle Drozd is a Deputy Vice President in the Policy and Research department at the Pharmaceutical Research and Manufacturers of America (PhRMA). Michelle focuses on issues related to how the pharmaceutical industry is adapting to the increasingly competitive and value-based healthcare environment.

Prior to joining PhRMA, Michelle worked in quality improvement and business planning at Partners Healthcare, an integrated delivery system. She also worked at RTI International as a contractor to the Centers for Medicare & Medicaid Services.

Michelle holds a BA in economics and public policy from Duke University and a SM in health policy and management from Harvard School of Public Health.

Michele Fisher, MBA, FACHE, FACMPE, CSMC is the Chief Contracting and Payer Relations Officer of UW Medicine Health System. UW Medicine Health System includes Harborview Medical Center, University of Washington Medical Center, Northwest Hospital and Medical Center, Valley Medical Center & Clinics, UW Neighborhood Clinics, UW Physicians, UW School of Medicine and Airlift Northwest. Michele has over 20 years’ experience in health care leadership positions. She has worked in health care in the Puget Sound area for the over 26 years in various business development, revenue cycle focused and clinical roles. UW Medicine is an accountable health organization (UW Medicine ACO) and has created its own UW Medicine Accountable Health Network (UW Medicine ACN).

Michele began her career at UW Medicine serving at Harborview Medical Center as the Director of Contracting and Payer Relations for nearly a year. In her current position, for over 5 years, she is responsible for the relationships with Payers, ACO negotiation and implementation (both on the ACN formation side and on the ACO direct to payer/employer side) for both the UW Medicine ACO and the UW Medicine ACN. She is also accountable for, among other items, the actuarial relationship for UW Medicine and the negotiation process of payer contracts and all aspects of payer or employer contract reporting within UW Medicine including Harborview Medical Center, UW Medical Center, Northwest Hospital, Valley Medical Center, UW Neighborhood Clinics, UW Physicians.

Before coming to UW Medicine, Michele worked in progressive leadership positions in her approximately 20 years at Overlake Hospital Medical Center, Virginia Mason Medical Center and Valley Medical Center.

Michele is a Fellow in of the American College of Healthcare Executives (FACHE), a Fellow in the American College of Medical Practice Executives (FACMPE) of the Medical Group Management Association (MGMA) Association, and CoC and CPC-h certified by AAPC (American Academy of Professional Coders). Additionally Michele is a Member of the Healthcare Financial Management Association (HFMA) and the Washington Mediation Association (WMA).

Michele has an Executive Certificate in Advanced negotiations from University of Notre Dame. She graduated from Taft University W. Edwards Deming School of Business with honors (Magna Cum Laude) with an MBA with an emphasis in Healthcare Administration, has a Bachelor of Science Degree in Finance and a Bachelors of Science Degree in Organizational behavior both from Central Washington University. Michele served several clinical roles as a Medical Assistant and ER Tech early on during her healthcare tenure.

Michele has been invited to speak locally to specialty focused special interest groups about healthcare contract trending, contract language interpretation and medical practice succession planning. Speaking nationally at ACO RISE (2013-2015) conferences and at CE events regarding Managed Care contracting. She has served as a volunteer speaker to the Washington State Academy of Pediatric Dentistry and volunteers at various venues throughout King County supporting community improvement projects and human rights.

Julie Locklear, PharmD, MBA is Vice President for Health Economics & Outcomes Research (HEOR) at EMD Serono, Inc, a business of Merck KGaA, Darmstadt, Germany. Dr. Locklear joined EMD Serono, Inc. in January 2013. In this role, she is responsible for establishing the US Health Economics & Outcomes Research team within the Medical Affairs Organization. Leadership of a team responsible for developing, executing and disseminating the value evidence of EMD Serono's portfolio of specialty products in the areas of oncology, immuno-oncology, immunology, neuroscience, infertility, and endocrinology. Ensures US payer customer needs are aligned with cross-functional partners across the US and Global organizations. Leads a team of in-house HEOR researchers who generate value evidence as well as field-based HEOR team who interact with formulary decision makers.

Her previous experience includes seven years as Global Payer Evidence Director at AstraZeneca Pharmaceuticals where her responsibilities focused on the development of successful global reimbursement dossiers across multiple therapeutic areas including inflammation, respiratory, neuroscience and autoimmune disorders. She has experience launching products, business development, market access, leading cross functional internal teams (direct and indirect management), external contract research organizations, and alliance management.

Prior to AstraZeneca, she worked for Janssen Pharmaceutica in a variety of health economic roles including both in-house and customer facing. Dr. Locklear received her Doctor of Pharmacy from the University of Rhode Island and a Masters in Business Administration from Saint Joseph’s University. She currently sits on the board of Network for Excellence in Health Innovation (NEHI) and sits on a number of executive-level real-world evidence (RWE) roundtable discussions.

LinkedIn Profile: https://www.linkedin.com/in/julie-locklear-5571837?trk=hp-identity-name

Ulrich Neumann, MSc, MA, FRSA, is a Senior Director at Analytica Laser in New York, where he leads the development of the company’s offering in outcomes-based contracting as well as other activities in commercial development. With a dual background in business administration and public management, he focuses on pharmaceutical reimbursement and pricing issues, as well as activities on the US political, legislative and regulatory landscape to assess policy drivers, enablers and challenges to market access. His business experience lies in defining product strategy, positioning, value messaging and brand development. The founder of two companies, Ulrich most recently ran the US division of a global provider of pharmaceutical market insights and b2b networking. Prior experience includes consulting work in market entry, marketing and political strategy for a diverse set of clients (incl. medical, non-profits, energy, aerospace and consumer goods firms). Ulrich is a graduate of the London School of Economics (Msc), University of Southern California (MA), University of Muenster (BA) and University Enschede (Bsc) and has published white papers and articles in major pharmaceutical trade publications, as well as two books in the policy field.

Edmund Pezalla, M.D., MPH, is Aetna's leading executive for issues related to pharmaceutical development, reimbursement strategy, and drug evaluation. He is active on projects in both the public and private sectors including: CDC and FDA as well as MIT's Center for Biomedical Innovation. Recently Dr. Pezalla served as a consultant for the President's Council of Advisors on Science and Technology for their report: Propelling Innovation in Drug Discovery, Development and Evaluation. Dr. Pezalla is also a member of the Advisory Board of the Connecticut Innovations Biosciences Fund.

Dr. Pezalla is currently leading Aetna's innovative partnership initiatives with device and pharmaceutical manufacturers including pay-for-performance and shared risk programs.

Previously Dr. Pezalla was Chief Clinical Officer for Aetna Pharmacy Management from July 2007 to July 2010. In that role he was responsible for formulary development, quality and utilization programs and clinical strategy. Prior to joining Aetna Dr. Pezalla was VP of clinical services at Prescription Solutions, the wholly owned PBM subsidiary of United Health.

Dr. Pezalla is a graduate of Georgetown University College of Arts and Sciences and Georgetown University School of Medicine. He also holds an MPH from the School of Public Health, University of California at Berkeley and completed a research fellowship and post-doctoral studies at the University of Michigan Schools of Medicine and Public Health.

• Special Government Employee, FDA Risk Communications Advisory Committee
• Associate Editor, Therapeutic Innovation & Regulatory Science (official DIA journal)
• Executive Advisory Board, the Galien Foundation
• Editorial Advisory Board, Food and Drug Policy Forum
• Advisory Board, Journal of Commercial Biotechnology
• Editorial Advisory Board, The Patient Magazine
• Board of Advisors, Digital Health Council
• Washington Drug Letter, Editorial Advisory Board
• Briefings on Drug Safety, Editorial Advisory Board
• Advisory Board, MedAd News
• Scientific Advisory Council. Animal Health Institute

Peter Pitts is President of the Center for Medicine in the Public Interest. A former member of the United States Senior Executive Service, Peter was FDA’s Associate Commissioner for External Relations, serving as senior communications and policy adviser to the Commissioner. He supervised FDA's Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. He served on the agency’s obesity working group and counterfeit drug taskforce and is a Special Government Employee (SGE) consultant to the FDA’s Risk Communications Advisory Committee.

Specific areas of global policy expertise include FDA policy and process, healthcare technology assessment and reimbursement issues, biosimilar development, Rx-to-OTC switching, risk management plans, GMP policies, pharmacy education programs, drug safety, DTC/ItP, Critical Path, personalized medicine, clinical trial transparency, IP protection, FDA reform, drug importation, counterfeiting, genetically modified food issues, food safety and security, recalls, nutritional labeling.

In 2010, he was named by Modern Healthcare magazine as one of the 300 “most powerful people in American healthcare.”

His comments and commentaries on health care policy issues regularly appear in The New York Times, The Los Angeles Times, The Washington Post, The Wall Street Journal, The Financial Times, Health Affairs, The Boston Globe, The Washington Times, The Chicago Tribune, The Chicago Sun Times, The San Francisco Examiner, Investor’s Business Daily, The Baltimore Sun, The Economist, Nature Biotechnology, The Journal of Life Sciences the BBC World Service, Fox News, and The NewsHour with Jim Lehrer, among others.

He has given healthcare policy presentations throughout Europe, Canada, and the United States, as well as in Russia, China,the Philippines, Malaysia, Saudi Arabia, Lebanon, Israel, Turkey, The United Arab Emirates, Jordan, Kenya, South Africa, Egypt, Algeria, Ukraine, Taiwan, Japan, Brazil, Mexico, Vietnam, and Columbia.

His book, Become Strategic or Die, is widely recognized as a cutting edge study of how leadership, in order to be successful over the long term, must be combined with strategic vision and ethical practice. He is the editor of Coincidence or Crisis, a discussion of global prescription medicine counterfeiting and Physician Disempowerment: A Transatlantic Malaise.

He has served as an adjunct professor at Indiana University’s School of Public and Environmental Affairs and Butler University. A graduate of McGill University, he is married to Jane Mogel, and has two sons.

Dr. Robert Popovian is Sr. Director, US Government Relations at Pfizer Inc. For the past 2 decades, Dr. Popovian has published and presented extensively on the impact of biopharmaceuticals and health policies on health care costs and clinical outcomes, including authorship in clinical and healthcare delivery journals and published expert source in Los Angeles Times, USA Today, Pink Sheet and Bloomberg News amongst many others. He also writes a monthly column published in Morning Consult regarding health policy and economic issues relevant to the biopharmaceutical industry. He currently serves as a board member for the Global Healthy Living Foundation.

Dr. Popovian is one of the few researchers who has studied and published both clinical and policy related economic analysis as well as one of a handful who have studied and published empirical data regarding emerging payment mechanisms in the US healthcare system. He was also one of the first to secure inclusion of health outcomes data regarding labeled indication of a biopharmaceutical.

Dr. Popovian completed his Doctorate in Pharmacy and Masters of Science in Pharmaceutical Economics and Policy degrees at the University of Southern California with honors. He has also completed a residency in Pharmacy Practice/Adult Internal Medicine and Infectious Diseases at the Los Angeles County – University of Southern California Hospital.

Throughout his healthcare career, John’s mission has been to define and build unique programs that are recognized as “best in class” for patient experience and outcomes. With extensive experience from both the pharmaceutical manufacture and within a large integrated health system, John embraces the opportunity to connect specialty patients and their providers to manufactures, payers, plan sponsors, and others, to create a patient-centric, clinical care team model that produces superior, demonstrable results in patient care.

John is a proud graduate of the University of Georgia, receiving his Master’s in Business Administration and Marketing from the University of South Carolina.

With more than 23 years of experience, Stephen counsels clients in the defense, technology, life sciences, manufacturing, services and food industries on supplies and service indefinite delivery, indefinite quantity (IDIQ) task order contracts, fixed-price, and cost reimbursement contracts and related Federal Acquisition Regulation provisions, subcontract negotiations and compliance, government contracts disputes, and federal debarment and suspension.

Stephen conducts investigations and prepares reports under the US Department of Veterans Affairs (VA), the US Department of Defense (DOD), and the US Department of State voluntary disclosure programs. He appears before the US Court of Federal Claims, US Courts of Appeals, the Armed Services Board of Contract Appeals, and the Civilian Board of Contract Appeals. He also represents clients in bid protests before the GAO and the US Court of Federal Claims.

With respect to federal healthcare supplies and services, Stephen counsels clients on VA, DOD, and US Department of Health and Human Services (HHS) procurements. He also advises on government pricing laws and regulations governing manufacturer participation in the Medicaid Drug Rebate, Medicare, 340B, TRICARE, and Veterans Healthcare Act programs; VA FSS contracts; and public policy affecting these programs.

Additionally, Stephen counsels clients on the implementation and review of complex government pricing systems, providing strategic advice on the government pricing, fraud, and abuse implications of commercial pricing and patient benefit programs.

Stephen E. Ruscus represents clients in government contracts procurement, US federal drug pricing programs, and in litigation before the Boards of Contract Appeals, the US Court of Federal Claims, and the US Government Accountability Office (GAO). He also advises in protest practice before the US Small Business Administration and in matters relating to federal procurement of commercial items and services, including those under Federal Supply Schedule contracts.

Dr. Tehseen Salimi, MD, MHA, is currently serving as Head of Medical Affairs for Primary care & Women’s Health at Merck. Prior to Joining Merck she has served in Medical Affairs leadership roles within several Pharmaceutical organizations including Roche , Sanofi , AstraZeneca & Trevena Prior to joining the Pharmaceutical industry she served in leadership positions within managed care organizations, including Cigna and Fallon Health care.

Dr. Salimi is a Healthcare Executive with over 25 years of experience leading transformative patient-centric initiatives to bridge the evidence & value gaps. Her leadership developed in complex and rapidly changing environments, is backed with strong tenure in managed care (US Payer) and global pharmaceutical arenas. Her work to develop evidence based frameworks including a model for integrating medical value into portfolio valuation & Medical Affairs strategy & planning process has been critical for customer-centric transformation.

During her tenure, Dr. Salimi was honored with several awards, including the Hippocratic award for connecting Science with Medical Practice , the Physician’s Recognition Award for Best Outcomes and the Superior Achievement Award at Cigna. She was also featured in the 1998 annual report of the National Committee for Quality Assurance (NCQA) for the Best Practice Quality Improvement Initiative. She attributes her success to commitment to Patient care, perseverance, and dedication to Innovation & learning.

Dr.Salimi is a physician by training and obtained her Preventive medicine fellowship from University of Massachusetts and a Masters in Health administration from a joint degree program at Clark and UMass.

BILL SARRAILLE is a senior member of the Healthcare Practice group and a nationally-recognized lawyer in healthcare law. Mr. Sarraille concentrates on a variety of healthcare matters, including Medicare and Medicaid reimbursement, coverage and coding, pharmaceutical price reporting, issues related to the marketing and promotion of pharmaceuticals and medical devices, internal investigations, clinical research issues, Stark and Anti-Kickback Law analyses, Medicare and Medicaid audits, healthcare acquisitions and due diligence, compliance program audits, managed care matters, healthcare contracts, administrative litigation, legislative matters, privacy and security, coverage for new devices and services, the Foreign Corrupt Practices Act, international compliance and healthcare contracting, the representation of witnesses and companies before Congressional Committees, and the defense of healthcare criminal and False Claims Act matters. Mr. Sarraille has defended clients in some of the largest healthcare fraud investigations brought by the U.S. Government.

Tom Scales is Vice President of National Accounts at GlaxoSmithKline. In this capacity, Tom leads a team of Field Vice Presidents, Account Directors and Account Managers responsible for managing the relationship between GSK and large health plans, PBMs, GPOs and government customers. Prior to this role Tom led the Respiratory and Neuroscience Brand Payer Marketing Team.

Tom joined GSK in 2010 following a successful ten-year career at Eli Lilly where he held leadership positions in marketing, payer strategy and account management in the US, Europe and Emerging Markets.

Prior to his career in pharmaceuticals Tom spent six years living in Paraguay where he had several jobs including Peace Corps Volunteer, Advisor to the Ministry of Industry and Commerce and Director of Investments for the City of Asuncion.

Tom received a BA from Vanderbilt University and an MBA from the University of Texas at Austin. Tom and his wife, Suse, have two daughters and reside in Cary, North Carolina.

William Shrank MD MSHS is an internal medicine physician who serves on the Faculty at Harvard Medical School and in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital. He has published well over 100 articles in the peer-reviewed literature focused on improving the safe, appropriate and cost-effective use of prescription medications. He founded and led the multi-disciplinary CVS Caremark Harvard Partnership for Improving Medication Adherence, received a Pioneer Award from the Robert Wood Johnson Foundation, and implemented a number of randomized controlled policy trials to improve adherence to chronic medications.

Until recently, Dr. Shrank served as the Director of the Rapid-Cycle Evaluation Group at the Center for Medicare and Medicaid Innovation at the Centers for Medicare and Medicaid Services. Dr. Shrank led the evaluation of a $10 billion health reform research agenda to develop and test new payment models aimed at reducing the cost and improving the quality of care in the U.S. Dr. Shrank was a key architect of the design of all new payment models tested at CMMI, and also led the intramural research enterprise at CMS.

Dr. Shrank serves or has served on national advisory committees for the FDA, AHRQ, CMS, HHS, ASPE, USP, and the American College of Physicians Foundation. He attended Brown University, received his M.D. from Cornell University, and earned an M.S. in Health Services from UCLA.

Dr. Randy Vogenberg is Principal, Institute for Integrated Healthcare, Greenville, SC; Co-Founder of Access Market Intelligence; and former National Health Benefits Thought Leader for Aon Consulting.

Dr. Vogenberg currently is the Pharmacy Advisor and Co-Project Leader with the Midwest Business Group on Health National Employer Biologics & Specialty Pharmacy Initiative. With Access Market Intelligence, he provides consulting on applying healthcare management intelligence to your strategic and tactical business decisions in solving complex health care system reform challenges.

A frequent speaker and author focusing on integrated health strategies and contemporary managed care or health system issues, Dr. Vogenberg has authored several books, including “Pharmacy Benefits: Benefit Design and Management” and an eLearning program on “Specialty Pharmacy and Biotechnology Medication Coverage” for the International Foundation of Employee Benefit Plans used by HR and benefit consultants now available through the HBI Institute.

He is an Editorial Board member of several publications, including Managed Healthcare, P&T;, and American Health & Drug Benefits. As a nationally recognized expert on health (medical & pharmacy) benefits and quality, he is an Adjunct Professor at both the University of Rhode Island College of Pharmacy and Presbyterian College School of Pharmacy, Adjunct Assistant Professor in the Department of Health Economics Research at the University of Illinois College of Pharmacy, and was a Senior Fellow with the Jefferson School of Population Health as well as the Department of Health Policy, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA..

Dr. Vogenberg holds a Bachelor of Science degree in Pharmacy and a Doctorate in Health Care Management. Additionally, he completed an Accredited Pharmacy Residency at the Brigham & Women’s Hospital/Harvard Medical School, Boston.

Pierre L Yong, MD, MPH, MS, is the Director of Quality Measurement in the Quality Measurement and Value-Based Incentives Group/Center for Clinical Standards and Quality at the Centers for Medicare & Medicaid Services (CMS). At CMS, he oversees measure development and analyses for a variety of CMS quality reporting and value-based purchasing programs. Previously, Pierre was the Director of Health Care Quality and Outcomes in the Office of the Assistant Secretary of Planning Evaluation at the U.S. Department of Health and Human Services, where he oversaw projects on value based purchasing, quality, comparative effectiveness research, and data infrastructure for patient-centered outcomes research. Pierre also previously worked at the Institute of Medicine, where he focused on a portfolio of projects related to value and costs in health care. As a Robert Wood Johnson Clinical Scholar at the University of Pennsylvania, his research focused on quality of care. Pierre received his medical degree from Brown Medical School, his Masters in Public Health from Columbia University, and his Masters in Science in Health Policy Research at the University of Pennsylvania. He completed his Internal Medicine training at New York Presbyterian Hospital, and most recently worked as a hospitalist at the District of Columbia Veterans Affairs Medical Center.